WO2007011896A3 - Method to inhibit proliferation and growth of metastases - Google Patents

Method to inhibit proliferation and growth of metastases Download PDF

Info

Publication number
WO2007011896A3
WO2007011896A3 PCT/US2006/027746 US2006027746W WO2007011896A3 WO 2007011896 A3 WO2007011896 A3 WO 2007011896A3 US 2006027746 W US2006027746 W US 2006027746W WO 2007011896 A3 WO2007011896 A3 WO 2007011896A3
Authority
WO
WIPO (PCT)
Prior art keywords
subject
growth
metastases
blood
inhibit proliferation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/027746
Other languages
French (fr)
Other versions
WO2007011896A2 (en
Inventor
Michael T Kirber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston University
Original Assignee
Boston University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston University filed Critical Boston University
Priority to CA002636367A priority Critical patent/CA2636367A1/en
Priority to US11/995,958 priority patent/US20100130904A1/en
Priority to AU2006270057A priority patent/AU2006270057A1/en
Priority to EP06787633A priority patent/EP1951336A2/en
Publication of WO2007011896A2 publication Critical patent/WO2007011896A2/en
Publication of WO2007011896A3 publication Critical patent/WO2007011896A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides a method to reduce the amount of undesired growth factors in the circulating blood of a subject to prevent tumor growth and proliferation during or after a wound healing and/or other local tissue repair process on a subject, comprising extracorporeal adsorption of growth factors from blood of the subject and return of the treated blood to the subject.
PCT/US2006/027746 2005-07-18 2006-07-18 Method to inhibit proliferation and growth of metastases Ceased WO2007011896A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002636367A CA2636367A1 (en) 2005-07-18 2006-07-18 Method to inhibit proliferation and growth of metastases
US11/995,958 US20100130904A1 (en) 2005-07-18 2006-07-18 Method to inhibit proliferation and growth of metastases
AU2006270057A AU2006270057A1 (en) 2005-07-18 2006-07-18 Method to inhibit proliferation and growth of metastases
EP06787633A EP1951336A2 (en) 2005-07-18 2006-07-18 Method to inhibit proliferation and growth of metastases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70011805P 2005-07-18 2005-07-18
US60/700,118 2005-07-18

Publications (2)

Publication Number Publication Date
WO2007011896A2 WO2007011896A2 (en) 2007-01-25
WO2007011896A3 true WO2007011896A3 (en) 2007-06-14

Family

ID=37451525

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/027746 Ceased WO2007011896A2 (en) 2005-07-18 2006-07-18 Method to inhibit proliferation and growth of metastases

Country Status (5)

Country Link
US (1) US20100130904A1 (en)
EP (1) EP1951336A2 (en)
AU (1) AU2006270057A1 (en)
CA (1) CA2636367A1 (en)
WO (1) WO2007011896A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007026877A1 (en) * 2007-06-08 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Use of fibroblast growth factor 7 (Fgf7) and the receptor Fgfr2b as biomarkers
MX2010003718A (en) * 2007-10-19 2010-04-21 Genentech Inc ANTI-TENB2 ANTIBODIES PRODUCED BY CISTEINE ENGINEERING AND PHARMACO AND ANTIBODY CONJUGATES.
US9694128B1 (en) * 2010-02-24 2017-07-04 Brian LeBerthon Device and method for administering an anti-cancer substance
JP2014520873A (en) 2011-07-18 2014-08-25 ザ ユニバーシティ オブ メルボルン Use of c-Fms antagonists
CN102393456B (en) * 2011-08-24 2014-02-12 北京正旦国际科技有限责任公司 A kind of test kit for detecting HPS
US9227005B2 (en) 2013-03-14 2016-01-05 Brian J LeBerthon Method and device for treating cancer
CN105378075B (en) 2013-03-15 2022-04-05 Atyr 医药公司 Histidyl-TRNA synthetase-FC conjugate
SG11201507871XA (en) 2013-04-12 2015-10-29 Morphosys Ag Antibodies targeting m-csf
CN103285826A (en) * 2013-06-28 2013-09-11 天津优纳斯生物科技有限公司 Blood purification adsorbing agent for restraining grown and transfer of tumor and application thereof
CN110536694A (en) 2017-04-20 2019-12-03 Atyr 医药公司 Compositions and methods for treating pulmonary inflammation
EP3735281B1 (en) 2018-01-05 2024-11-27 Path Ex, Inc. Device for the capture and removal of disease material from fluids
CA3096222A1 (en) 2018-04-06 2019-10-10 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
FR3099373B1 (en) * 2019-08-01 2024-11-08 I Ceram Material for capturing circulating cells in blood, preparation method and use
CN114746120B (en) 2019-10-03 2024-07-30 Atyr医药公司 Compositions and methods comprising anti-NRP 2 antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1142633A1 (en) * 2000-02-14 2001-10-10 Kaneka Corporation Adsorbent for transforming growth factor-Beta, method for removing the transforming growth factor-Beta by adsorption and adsorber packed with the adsorbent
EP1466925A1 (en) * 2001-12-28 2004-10-13 Kirin Beer Kabushiki Kaisha Antibodies against fibroblast growth factor 23

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4643718A (en) * 1983-02-22 1987-02-17 Applied Immunesciences, Inc. Therapeutic apheresis
US5753227A (en) * 1993-07-23 1998-05-19 Strahilevitz; Meir Extracorporeal affinity adsorption methods for the treatment of atherosclerosis, cancer, degenerative and autoimmune diseases
US6379708B1 (en) * 1999-11-20 2002-04-30 Cytologic, Llc Method for enhancing immune responses in mammals
WO2005107802A2 (en) * 2004-04-30 2005-11-17 Biopheresis Technologies, Llc Method and system to remove soluble tnfr1, tnfr2, and il2 in patients

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1142633A1 (en) * 2000-02-14 2001-10-10 Kaneka Corporation Adsorbent for transforming growth factor-Beta, method for removing the transforming growth factor-Beta by adsorption and adsorber packed with the adsorbent
EP1466925A1 (en) * 2001-12-28 2004-10-13 Kirin Beer Kabushiki Kaisha Antibodies against fibroblast growth factor 23

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BEN-BARUCH A: "Host microenvironment in breast cancer development: inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions.", BREAST CANCER RESEARCH : BCR. 2003, vol. 5, no. 1, 2003, pages 31 - 36, XP002412853, ISSN: 1465-542X *
KLEIN E ET AL: "Affinity adsorption devices prepared from microporous poly(amide) hollow fibers and sheet membranes", JOURNAL OF MEMBRANE SCIENCE, ELSEVIER SCIENTIFIC PUBL.COMPANY. AMSTERDAM, NL, vol. 129, no. 1, 25 June 1997 (1997-06-25), pages 31 - 46, XP004082285, ISSN: 0376-7388 *
KUNINAKA SHINJI ET AL: "Direct influences of pro-inflammatory cytokines (IL-1beta, TNF-alpha, IL-6) on the proliferation and cell-surface antigen expression of cancer cells", CYTOKINE, vol. 12, no. 1, January 2000 (2000-01-01), pages 8 - 11, XP002412854, ISSN: 1043-4666 *
LAZARUS H M ET AL: "SELECTIVE IN-VIVO REMOVAL OF RHEUMATOID FACTOR BY AN EXTRACORPOREAL TREATMENT DEVICE IN RHEUMATOID ARTHRITIS PATIENTS", TRANSFUSION (BETHESDA), vol. 31, no. 2, 1991, pages 122 - 128, XP009076549, ISSN: 0041-1132 *
SAOTOME TAKAO ET AL: "A case of severe acute pancreatitis treated with CTR-001 direct hemoperfusion for cytokine apheresis.", THERAPEUTIC APHERESIS AND DIALYSIS : OFFICIAL PEER-REVIEWED JOURNAL OF THE INTERNATIONAL SOCIETY FOR APHERESIS, THE JAPANESE SOCIETY FOR APHERESIS, THE JAPANESE SOCIETY FOR DIALYSIS THERAPY AUG 2005, vol. 9, no. 4, August 2005 (2005-08-01), pages 367 - 371, XP002412855, ISSN: 1744-9979 *
SHIMIZU TOMOHARU ET AL: "Extracorporeal cytokine apheresis for sepsis: CTR as a new therapeutic adsorbent.", CRITICAL CARE MEDICINE. MAR 2006, vol. 34, no. 3, March 2006 (2006-03-01), pages 926 - 927, XP009076551, ISSN: 0090-3493 *
SOLTYS P J ET AL: "IN VITRO CHARACTERIZATION OF A MEMBRANE-BASED LOW-DENSITY LIPOPROTEIN AFFINITY ADSORPTION DEVICE", BLOOD PURIFICATION, KARGER, BASEL, CH, vol. 16, no. 3, May 1998 (1998-05-01), pages 123 - 134, XP009010931, ISSN: 0253-5068 *

Also Published As

Publication number Publication date
EP1951336A2 (en) 2008-08-06
US20100130904A1 (en) 2010-05-27
AU2006270057A1 (en) 2007-01-25
CA2636367A1 (en) 2007-01-25
WO2007011896A2 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
WO2007051179A3 (en) Partially covered stent devices and methods of use
WO2007011896A3 (en) Method to inhibit proliferation and growth of metastases
WO2008005888A3 (en) Atherectomy devices and methods
ATE376446T1 (en) USE OF N-HYDROXYALKYL-O-BENZYLCHITOSANES FOR HAIR TREATMENT
WO2009126309A3 (en) Atherectomy devices and methods
WO2009017863A3 (en) Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification
WO2008073582A3 (en) Biological tissue for surgical implantation
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
EP1940300A4 (en) Method for treating subcutaneous tissues
WO2003028802A3 (en) Devices for treating atrial fibrilation
WO2009016451A3 (en) Method and compound for the treatment of articular diseases or articular pain, or for the treatment of skin for aesthetic or other purposes, and the method of preparation of the compound
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
WO2006099610A3 (en) Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy
WO2005060960A3 (en) Use of histamine to treat bone disease
WO2005110479A3 (en) Treatments for pancreatic cancer
WO2008080532A3 (en) Medical fabric
EP2716285A3 (en) New method for identifying compounds useful for treating and/or preventing diseases associated with bone loss
WO2008014603A3 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
WO2008008468A3 (en) Compositions and methods for fat reduction
EP1838260A4 (en) System and method for the treatment of heart tissue
WO2006116374A3 (en) Surface treatments for promoting selective tissue attachment to medical implants
WO2008059009A3 (en) Factor v mutants for hemostasis in hemophilia
WO2007142942A3 (en) Method of improving wound healing
WO2008029264A3 (en) Method of treating bone cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006270057

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006787633

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2636367

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11995958

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2006270057

Country of ref document: AU

Date of ref document: 20060718

Kind code of ref document: A